Editorials

Unraveling the Phenotypic Variability of Juvenile Idiopathic Arthritis across Races or Geographic Areas — Key to Understanding Etiology and Genetic Factors?
A. Consolaro, A. Ravelli .................................................. 683

Pain Management for the Young Adult Rheumatology Patient in an Era of Medicinal Marijuana Legalization

Ghost Busting, Taking the Sheet Off the Ghost
R.J. Moots, K. Wilson, E.D. Silverman ........................................ 689

Articles

How to Motivate Patients with RA to Quit Smoking
H.E. Harris, F. Tweedie, M. White, K. Samson ......................... 691

Early Remission Is a Realistic Target in a Majority of Patients with DMARD-naive RA

Effect of RA on Longterm Sickness Absence in 1994-2011: A Danish Cohort Study
S.M. Hansen, M.L. Hetland, J. Pedersen, M. Østergaard, T.S. Rubak, J.B. Bjorner .......................... 707

Achievement of Remission and Low Disease Activity Definitions in Patients with RA in Clinical Practice: Results from the NOR-DMARD Study
T. Uhlig, E. Lie, V. Norvang, et al ........................................... 716

Why Do Patients with Chronic Inflammatory Rheumatic Diseases Discontinue Their Biologics? An Assessment of Patients’ Adherence Using a Self-report Questionnaire
A.L. Betegnie, A. Gauchet, A. Lehmann, et al ................................. 724

Myeloid-related Protein 8/14 Levels in RA: Marker of Disease Activity and Response to MTX
P.S. Patro, A. Singh, R. Misra, A. Aggarwal ................................. 731

Clinical Characteristics and Cytokine Profiles of Organizing Pneumonia in Patients with RA Treated with or without Biologics

Longitudinal Evaluation of Lipoprotein Variables in SLE Reveals Adverse Changes with Disease Activity and Prednisone and More Favorable Profiles with HCQ Therapy
L. Durcan, D.A. Winegar, M.A. Connelly, J.D. Otvos, L.S. Magder, M. Petri .................................................. 745

Assessment of Fatigue in SpA and Its Association with Disease Activity
C. López-Medina, R.E. Schiotis, P. Font-Ugalde, et al, on behalf of the REGISpONSEr Working Group ........................................ 751

Etanercept Increases Bone Mineral Density in AS, but Does Not Prevent Vertebral Fractures: Results of a Prospective Observational Cohort Study

Disparities in Outcomes for African Americans and Whites Undergoing Total Knee Arthroplasty: A Systematic Literature Review
S.M. Goodman, M.L. Parks, K. McHugh, et al ................................. 765

Inflammatory Cells in Patients with Endstage Knee OA: A Comparison between the Synovium and the Infrapatellar Fat Pad

Development of a Rheumatology-specific Patient Concerns Inventory and Its Use in the Rheumatology Outpatient Clinic Setting

How to Attract Trainees, a Pan-Canadian Perspective: Phase 1 of the “Training the Rheumatologists of Tomorrow” Project
A. Cividino, V. Bakowsky, S. Barr, et al ........................................ 788

Pediatric Rheumatology

Phenotypic Characterization of JIA in African American Children
L. Fitzpatrick, K.A. Broadaway, L. Ponder, et al, for the CARR Registry Investigators ........................................ 799

Birth Outcomes in Women with a History of JIA

Carotid Atherosclerosis in Adult Patients with Persistently Active JIA Compared with Healthy Controls
K. Evensen, H.A. Aulie, O.M. Ronning, B. Flato, D. Russell ................................. 810

Two-year Efficacy and Safety of Etanercept in Pediatric Patients with Extended Oligoarthritis, Enthesitis-related Arthritis, or PsA
T. Constantin, I. Foeldvari, J. Vojinovic, et al, for the Paediatric Rheumatology International Trials Organisation (PRINTO) ........................................ 816

Contents continued on page xx